SEC Form 4 · accession 0001209191-19-010352
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
G Bradley Cole
Officer — CFO
Period of report
Feb 12, 2019
Accepted (ET)
Feb 14, 2019 · 5:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 12, 2019 | M | 5,000 | $17.18 | A | 53,067 | I | Held by the Cole Family Trust |
| Common StockF2,F3,F4,F1 | Feb 12, 2019 | S | 5,000 | $80.3452 | D | 48,067 | I | Held by the Cole Family Trust |
| Common StockF1 | Feb 12, 2019 | M | 10,000 | $22.98 | A | 58,067 | I | Held by the Cole Family Trust |
| Common StockF5,F3,F6,F1 | Feb 12, 2019 | S | 5,935 | $80.8907 | D | 52,132 | I | Held by the Cole Family Trust |
| Common StockF5,F3,F7,F1 | Feb 12, 2019 | S | 4,065 | $81.4788 | D | 48,067 | I | Held by the Cole Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F8 | $17.18 | Feb 12, 2019 | M | 5,000 | D | — | Feb 18, 2020 | Common Stock | 5,000 | 26,471 | D |
| Employee Stock Option (right to buy)F9 | $22.98 | Feb 12, 2019 | M | 10,000 | D | — | Jan 27, 2021 | Common Stock | 10,000 | 26,424 | D |
Explanation of responses
- F1Includes an aggregate of 20,554 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F2These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on June 4, 2018.
- F3Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F4Represents weighted average sale price. Actual sale prices ranged from $80.03 to $80.78.
- F5These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 23 2018.
- F6Represents weighted average sale price. Actual sale prices ranged from $80.41 to $81.40.
- F7Represents weighted average sale price. Actual sale prices ranged from $81.42 to $81.73.
- F8The option became exercisable as to 25% of the shares on February 18, 2011, and became exercisable as to 1/48th of the shares each full month thereafter.
- F9The option became exercisable as to 25% of the shares on January 27, 2012, and became exercisable as to 1/48th of the shares each full month thereafter.